慢性肾脏病 5 期且有继发性甲状旁腺功能亢进生化证据的患者是否应使用拟钙剂治疗？欧洲肾脏协会-欧洲透析和移植协会立场声明。
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.
机构信息
Renal and Transplantation Department, Guy's and St Thomas' Hospitals, London, UK.
Nephrology Department, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania.
出版信息
Nephrol Dial Transplant. 2015 May;30(5):698-700. doi: 10.1093/ndt/gfv050. Epub 2015 Mar 4.
PMID:25928337
Abstract
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
摘要
本文反映了 CKD-MBD 工作组的立场，该工作组是 ERA-EDTA 的一个官方工作组，也是 ERBP 顾问委员会的成员，ERBP 是 ERA-EDTA 的官方指南制定机构，本文基于最近的两项荟萃分析，讨论了在 CKD 5D 期患者中使用钙敏感受体激动剂的问题。
Zotero 插件